Impact of COVID-19 on the Management of Diabetic Retinopathy

Abstract

Diabetic retinopathy (DR) is one of the most common causes of vision loss in people across the world. COVID- Despite the fact that early diagnosis and management guidelines for DR have considerably lowered burden of disease, 19 disease outbreak limitations have had an impact on actual world clinical management in the care of DR patients. This research includes the most latest treatment guidelines and outcomes for DR in the context of the outbreak. When contrasted to equivalent instants of time in 2019, intravitreal doses for DR have declined dramatically globally during the outbreak, spanning from around 30 percent to around 100percent reduction. After a substantial amount of time, several research on operational findings demonstrate a loss in visual acuity. In the treatment of DR, changing practice methods have led to lower intravitreal doses and cumulative loss of vision acuity during follow-up. It will be vital to continue reviewing practise guidelines as more COVID mutations arise.